Vivi Ann Flørenes, Ph.D.
Research group leader
Division of Pathology
Rikshospitalet
Montebello
0310 Oslo
Norway
Office: + (47) 2293
Fax: + (47) 22508554
email: rut.holm@radiumhospitalet.no
Training:
Expertise:
Research Interests:
New biomarkers important for development and progression of malignant melanoma
Other Links:
Selected Publications:
Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B.
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma.
Cancer. 2008 Jan 1;112(1):84-93.
Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA.
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
Cancer. 2007 Sep 15;110(6):1264-71
Davidson B, Zhang Z, Kleinberg L, Li M, Flørenes VA, Wang TL, Shih IeM.
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5944-50.
Jørgensen K, Davidson B, Flørenes VA.
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma.
Mod Pathol. 2006 Nov;19(11):1446-55. Epub 2006 Sep 1.
Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA.
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.
Am J Clin Pathol. 2005 Oct;124(4):528-36.
Jørgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Flørenes VA.
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2.
Biochem Biophys Res Commun. 2005 Apr 1;329(1):266-74.
Torlakovic EE, Bilalovic N, Nesland JM, Torlakovic G, Flørenes VA.
Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis.
Mod Pathol. 2004 Nov;17(11):1400-6.
Flørenes VA, Skrede M, Jørgensen K, Nesland JM.
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival.
Melanoma Res. 2004 Jun;14(3):173-81.